Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Paschalis Ntolios

Showing results (21-30 of 31) with videos related to

Pageof 4
Sort By:
Journal of Thoracic Disease|July 10, 2020
Clinical long-term outcome of non-specific pleuritis (NSP) after surgical or medical thoracoscopyGeorgia Karpathiou, Stavros Anevlavis, Olivier Tiffet, et al.
Frontiers in Medicine|February 3, 2018
Corrigendum: Longitudinal "Real-World" Outcomes of Pirfenidone in Idiopathic Pulmonary Fibrosis in GreeceArgyrios Tzouvelekis, Theodoros Karampitsakos, Paschalis Ntolios, et al.
Journal of Translational Medicine|July 17, 2013
A prospective, non-randomized, no placebo-controlled, phase Ib clinical trial to study the safety of the adipose derived stromal cells-stromal vascular fraction in idiopathic pulmonary fibrosisArgyris Tzouvelekis, Vassilis Paspaliaris, George Koliakos, et al.
Frontiers in Medicine|December 15, 2017
Longitudinal "Real-World" Outcomes of Pirfenidone in Idiopathic Pulmonary Fibrosis in GreeceArgyrios Tzouvelekis, Theodoros Karampitsakos, Paschalis Ntolios, et al.
Pulmonary Pharmacology & Therapeutics|January 26, 2018
Safety and efficacy of nintedanib in idiopathic pulmonary fibrosis: A real-life observational study in GreeceArgyrios Tzouvelekis, Theodoros Karampitsakos, Maria Kontou, et al.
BMC Research Notes|November 28, 2012
Expression of hypoxia-inducible factor (HIF)-1a-vascular endothelial growth factor (VEGF)-inhibitory growth factor (ING)-4- axis in sarcoidosis patientsArgyris Tzouvelekis, Paschalis Ntolios, Andreas Karameris, et al.
Biomed Research International|July 11, 2013
Increased expression of epidermal growth factor receptor (EGF-R) in patients with different forms of lung fibrosisArgyris Tzouvelekis, Paschalis Ntolios, Andreas Karameris, et al.
Pulmonary Pharmacology & Therapeutics|December 25, 2019
Lung cancer in patients with Idiopathic Pulmonary Fibrosis. A retrospective multicenter study in GreeceArgyris Tzouvelekis, Theodoros Karampitsakos, Georgia Gomatou, et al.
Diagnostics (Basel, Switzerland)|May 1, 2025
Complete Blood Cell Count Parameters Predict Mortality in Patients with Hypersensitivity PneumonitisMatthaios Katsaras, Vasilina Sotiropoulou, Effrosyni Manali, et al.
Journal of Cancer|June 22, 2026
CellVizio<sup>®</sup> System for Mesothorax Lymphadenopathy Rapid on Site, 18G needle: Pros and ConsPaul Zarogoulidis, Wolfgang Hofenforst-Schwidt, Haidong Huang, et al.
Pageof 4

Showing results (21-30 of 31) with videos related to

Sort By:
Pageof 4
Journal of Thoracic Disease|July 10, 2020
Clinical long-term outcome of non-specific pleuritis (NSP) after surgical or medical thoracoscopyGeorgia Karpathiou, Stavros Anevlavis, Olivier Tiffet, et al.
Frontiers in Medicine|February 3, 2018
Corrigendum: Longitudinal "Real-World" Outcomes of Pirfenidone in Idiopathic Pulmonary Fibrosis in GreeceArgyrios Tzouvelekis, Theodoros Karampitsakos, Paschalis Ntolios, et al.
Journal of Translational Medicine|July 17, 2013
A prospective, non-randomized, no placebo-controlled, phase Ib clinical trial to study the safety of the adipose derived stromal cells-stromal vascular fraction in idiopathic pulmonary fibrosisArgyris Tzouvelekis, Vassilis Paspaliaris, George Koliakos, et al.
Frontiers in Medicine|December 15, 2017
Longitudinal "Real-World" Outcomes of Pirfenidone in Idiopathic Pulmonary Fibrosis in GreeceArgyrios Tzouvelekis, Theodoros Karampitsakos, Paschalis Ntolios, et al.
Pulmonary Pharmacology & Therapeutics|January 26, 2018
Safety and efficacy of nintedanib in idiopathic pulmonary fibrosis: A real-life observational study in GreeceArgyrios Tzouvelekis, Theodoros Karampitsakos, Maria Kontou, et al.
BMC Research Notes|November 28, 2012
Expression of hypoxia-inducible factor (HIF)-1a-vascular endothelial growth factor (VEGF)-inhibitory growth factor (ING)-4- axis in sarcoidosis patientsArgyris Tzouvelekis, Paschalis Ntolios, Andreas Karameris, et al.
Biomed Research International|July 11, 2013
Increased expression of epidermal growth factor receptor (EGF-R) in patients with different forms of lung fibrosisArgyris Tzouvelekis, Paschalis Ntolios, Andreas Karameris, et al.
Pulmonary Pharmacology & Therapeutics|December 25, 2019
Lung cancer in patients with Idiopathic Pulmonary Fibrosis. A retrospective multicenter study in GreeceArgyris Tzouvelekis, Theodoros Karampitsakos, Georgia Gomatou, et al.
Diagnostics (Basel, Switzerland)|May 1, 2025
Complete Blood Cell Count Parameters Predict Mortality in Patients with Hypersensitivity PneumonitisMatthaios Katsaras, Vasilina Sotiropoulou, Effrosyni Manali, et al.
Journal of Cancer|June 22, 2026
CellVizio<sup>®</sup> System for Mesothorax Lymphadenopathy Rapid on Site, 18G needle: Pros and ConsPaul Zarogoulidis, Wolfgang Hofenforst-Schwidt, Haidong Huang, et al.
Pageof 4